Effect of Two-Day Atorvastatin Pretreatment on the Incidence of Periprocedural Myocardial Infarction Following Elective Percutaneous Coronary Intervention: A Single-Center, Prospective, and Randomized Study

Josef Veselka(Universitat Autònoma de Barcelona), David Tesař(Charles University), David Zemánek, Martin Malý(Charles University), Lucie Martinkovičová(Charles University), Radka Adlová(Charles University), Petr Hájek(University Hospital in Motol)

The American Journal of Cardiology

June 25, 2009

10.1016/j.amjcard.2009.04.048

Cited by 41

Related Papers

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2020|1.2k

Effect of Intra-arrest Transport, Extracorporeal Cardiopulmonary Resuscitation, and Immediate Invasive Assessment and Treatment on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest

|JAMA|2022|674

Long‐term health outcome and mortality evaluation after invasive coronary treatment using drug eluting stents with or without the IVUS guidance. Randomized control trial. HOME DES IVUS

|Catheterization and Cardiovascular Interventions|2009|190

Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population

|European Heart Journal|2014|106

A FTO variant and risk of acute coronary syndrome

|Clinica Chimica Acta|2010|65